ADVISORY, June 29, 2017 (GLOBE NEWSWIRE) --
Aileron Therapeutics (Nasdaq:ALRN), a clinical-stage biopharmaceutical company advancing a novel class of therapeutics called stapled peptides, will visit the Nasdaq MarketSite in Times Square.
In honor of the occasion, Joseph A Yanchik III, President & CEO, will ring the Closing Bell.
Nasdaq MarketSite – 4 Times Square – 43rd & Broadway – Broadcast Studio
Thursday, June 29, 2017 – 3:45 p.m. to 4:00 p.m. ET
Aileron Media Contact:
Brad Miles, BMC Communications
Fiber Line (Encompass Waterfront): 4463
Gal 3C/06C 95.05 degrees West
18 mhz Lower
DL 3811 Vertical
For multimedia features such as exclusive content, photo postings, status updates and video of bell ceremonies, please visit our Facebook page:
For photos from ceremonies and events, please visit our Instagram page:
For livestream of ceremonies and events, please visit our YouTube page:
For news tweets, please visit our Twitter page:
For exciting viral content and ceremony photos, please visit our Tumblr page:
A live stream of the Nasdaq Closing Bell will be available at:
To obtain a hi-resolution photograph of the Market Close, please go to http://business.nasdaq.com/discover/market-bell-ceremonies and click on the market close of your choice.
About Aileron Therapeutics
Aileron is a clinical-stage biopharmaceutical company advancing stapled peptides, a novel class of therapeutics for cancers and other diseases. Stapled peptides are chemically stabilized alphahelical peptides that are modified to improve their stability and cell penetrability while maintaining high affinity for large protein surfaces. Our lead product candidate ALRN-6924, which is being evaluated in multiple clinical trials, is designed to reactivate p53-mediated tumor suppression by targeting both primary p53 suppressor proteins, MDMX and MDM2. The p53 protein is long known for its central role in preventing the initiation and progression of most solid and liquid tumors, and its inactivation is essential for the formation of virtually all cancers. We believe that ALRN-6924 is the first and only product candidate in clinical development that can inhibit both MDMX and MDM2, which we believe, based on published data and our preliminary clinical results, are equally important in restoring p53 function as the body’s first line of defense against cancer. Our goal is to use our stapled peptide drug platform to create first-in-class therapeutics, like ALRN-6924, that may be able to address historically undruggable targets and complex mechanisms that underlie many diseases with high unmet medical need.
Nasdaq (Nasdaq:NDAQ) is a leading global provider of trading, clearing, exchange technology, listing, information and public company services. Through its diverse portfolio of solutions, Nasdaq enables customers to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today's global capital markets. As the creator of the world's first electronic stock market, its technology powers more than 90 marketplaces in 50 countries, and 1 in 10 of the world's securities transactions. Nasdaq is home to 3,800 total listings with a market value of $11 trillion. To learn more, visit: http://business.nasdaq.com
In This StoryNDAQ
Nasdaq Press Center
Read the latest press releases, request a press kit, and get in touch with our press team.